Turning Point Therapeutics, Inc. announced the appointment of Andrew Partridge as executive vice president and chief commercial officer, effective July 13, 2020. Mr. Partridge joins the company from Centrexion Therapeutics, where he served as both chief operating officer and chief commercial officer. He was previously with Vertex Pharmaceuticals for 5 years, most recently as senior vice president and head of North American commercial operations where he built the team to successfully launch multiple cystic fibrosis therapies and new indications.